RT-4Homo sapiens (Human)Cancer cell line

Also known as: RT4, RT4P

🤖 AI SummaryBased on 14 publications

Quick Overview

Human bladder cancer cell line for research on tumor biology and therapies.

Detailed Summary

RT-4 is a human bladder cancer cell line derived from transitional cell carcinoma. It is widely used in cancer research for studying tumor progression, invasion mechanisms, and therapeutic responses. The cell line exhibits characteristics of well-differentiated transitional epithelium and has been utilized in in vitro models to investigate bladder cancer invasion and treatment efficacy. RT-4 is notable for its ability to form stratified epithelial layers and its use in assessing the effects of various compounds on tumor cell behavior. It has also been employed in studies examining the role of specific genetic alterations, such as 9p21 deletions, in bladder cancer development and progression.

Research Applications

Tumor invasion and metastasis studiesDrug screening and therapeutic response testingGenetic and molecular mechanism investigationsIn vitro models for bladder cancer research

Key Characteristics

Well-differentiated transitional epitheliumStratified epithelial layer formation9p21 deletions associated with tumor progressionUse in in vitro invasion assays
Generated on 6/14/2025

Basic Information

Database IDCVCL_0036
SpeciesHomo sapiens (Human)
Tissue SourceUrinary bladder[UBERON:UBERON_0001255]

Donor Information

Age63
Age CategoryAdult
SexMale
Racecaucasian

Disease Information

DiseaseBladder carcinoma
LineageBladder/Urinary Tract
SubtypeBladder Urothelial Carcinoma
OncoTree CodeBLCA

DepMap Information

Source TypeATCC
Source IDACH-000242_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
Gene deletionCDKN2A-HomozygousPossiblePubMed=26870271
Gene fusionFGFR3FGFR3-TACC3--from parent cell line RT-4
MutationSimpleTERTc.1-124C>T (c.228C>T) (C228T)UnspecifiedIn promoterfrom parent cell line Hep-G2
MutationSimpleTSC1p.Leu557Cysfs*72 (c.1669delC)Homozygous-from parent cell line RT-4
MutationNone reportedTP53---PubMed=19787792

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X,Y
CSF1PO
10,12
D13S317
8
D16S539
9
D18S51
15,17
D19S433
13
D21S11
30,32.2
D2S1338
18,19
D3S1358
15
D5S818
11,12
D7S820
9,12
D8S1179
13,15
FGA
22,24
Penta D
12
Penta E
7,10
TH01
9,9.3
TPOX
8,11
vWA
14,17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.

van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.

Nat. Commun. 10:3574.1-3574.11(2019).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Tissue typing of cells in culture. III. HLA antigens of established human cell lines. Attempts at typing by the mixed hemadsorption technique.

Espmark J.A., Ahlqvist-Roth L., Sarne L., Persson A.

Tissue Antigens 11:279-286(1978).

One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.

Fogh J., Fogh J.M., Orfeo T.

J. Natl. Cancer Inst. 59:221-226(1977).

Cultivation, characterization, and identification of human tumor cells with emphasis on kidney, testis, and bladder tumors.

Fogh J.

Natl. Cancer Inst. Monogr. 49:5-9(1978).

Absence of HeLa cell contamination in 169 cell lines derived from human tumors.

Fogh J., Wright W.C., Loveless J.D.

J. Natl. Cancer Inst. 58:209-214(1977).

Markers of neoplastic transformation in epithelial cell lines derived from human carcinomas.

Marshall C.J., Franks L.M., Carbonell A.W.

J. Natl. Cancer Inst. 58:1743-1751(1977).

Alkaline phosphatase activity in human bladder tumor cell lines.";

Benham F.J., Cottell D.C., Franks L.M., Wilson P.D.

J. Histochem. Cytochem. 25:266-274(1977).

HeLa cells and RT4 cells.";

Franks L.M., Rigby C.C.

Science 188:168-168(1975).

Human tumor lines for cancer research.";

Fogh J.

Cancer Invest. 4:157-184(1986).

Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines.

Franks L.M.

Cancer Res. 46:3630-3636(1986).

A human tissue culture cell line from a transitional cell tumour of the urinary bladder: growth, chromosome pattern and ultrastructure.

Rigby C.C., Franks L.M.

Br. J. Cancer 24:746-754(1970).

Polymorphic enzyme analysis of cultured human tumor cell lines.";

Dracopoli N.C., Fogh J.

J. Natl. Cancer Inst. 70:469-476(1983).

Human urologic cancer cell lines.";

Williams R.D.

Invest. Urol. 17:359-363(1980).

Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.

Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.

Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).

Identity of some human bladder cancer cell lines.";

O'Toole C.M., Povey S., Hepburn P.J., Franks L.M.

Nature 301:429-430(1983).

HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines.

Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.

J. Natl. Cancer Inst. 66:1003-1012(1981).

Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.

Rousset M., Zweibaum A., Fogh J.

Cancer Res. 41:1165-1170(1981).

p53 mutations in bladder carcinoma cell lines.";

Lippa M., Hatzivassiliou G., Tan J.

Oncol. Res. 6:569-579(1994).

The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes.

Stadler W.M., Olopade O.I.

Urol. Res. 24:239-244(1996).

Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer.

Markl I.D.C., Jones P.A.

Cancer Res. 58:5348-5353(1998).

Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion.

Harris A.L.

Br. J. Cancer 84:558-564(2001).

Molecular genetic analysis of chromosome 9 candidate tumor-suppressor loci in bladder cancer cell lines.

Coulter J., Kennedy W.J., Skilleter A., Habuchi T., Knowles M.A.

Genes Chromosomes Cancer 34:86-96(2002).

Assessment by M-FISH of karyotypic complexity and cytogenetic evolution in bladder cancer in vitro.

Knowles M.A.

Genes Chromosomes Cancer 43:315-328(2005).

PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.

Carrato A., Tardon A., Serra C., Real F.X.

Cancer Res. 66:7401-7404(2006).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

TSC1 involvement in bladder cancer: diverse effects and therapeutic implications.

Kwiatkowski D.J.

J. Pathol. 230:17-27(2013).

Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.

Orntoft T.F., Zuiverloon T.C.M., Malats N., Zwarthoff E.C., Real F.X.

Eur. Urol. 65:360-366(2014).

Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.

Hurst C.D., Platt F.M., Knowles M.A.

Eur. Urol. 65:367-369(2014).

Identification of mutations in distinct regions of p85 alpha in urothelial cancer.

Knowles M.A.

PLoS ONE 8:E84411-E84411(2013).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.

Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.

OncoImmunology 3:e954893.1-e954893.12(2014).

The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.

Chanock S.J., Valencia A., Real F.X.

BMC Genomics 16:403.1-403.16(2015).

Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics.

Limbart D.M., Rodel F., Wezel F., Haferkamp A., Cinatl J. Jr.

Transl. Oncol. 8:210-216(2015).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.

Tsang S.X., Cai Z.-M., Wu S., Dean M., Costello J.C., Theodorescu D.

Oncogene 36:35-46(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

FGFR3-TACC3 cancer gene fusions cause mitotic defects by removal of endogenous TACC3 from the mitotic spindle.

Sarkar S., Ryan E.L., Royle S.J.

Open Biol. 7:170080.1-170080.11(2017).

Systematic review: characteristics and preclinical uses of bladder cancer cell lines.

Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.

Bladder Cancer 4:169-183(2018).